
    
      It's a randomised crossover clinical trial. Subjects: chronic hemodialysis patients. All
      subjects will be randomised to 2 groups. Subjects in first group will receive 4 weeks
      transdermal clonidine plus regular antihypertensive agents treatments first, 2weeks wash-out
      then and 4 weeks antihypertensive agents without transdermal clonidine. The other group will
      receive 4 weeks antihypertensive agents without transdermal clonidine first, 2weeks wash-out
      then and 4 weeks transdermal clonidine plus regular antihypertensive agents treatments.
      Ambulatory blood pressure, echocardiography, and biochemistry will be detected.
    
  